Jul. 25, 2019—Men are more susceptible to progressive kidney disease than women; new VUMC studies point to differences in the expression and activation of the EGF receptor.
Oct. 16, 2018—Raymond Harris, Ming-Zhi Zhang and colleagues suggest pathways activated by the epidermal growth factor receptor may be promising targets for treating diabetic kidney disease.
Sep. 28, 2018—Biochemistry professor Richard Caprioli, director of the Mass Spectrometry Research Center, and Jeff Spraggins, research assistant professor of biochemistry, and their team will build a platform to molecularly characterize cells.
Aug. 17, 2018—ianchun Chen, Raymond Harris and colleagues have identified a potential new target for treating acute kidney injury.
Jun. 28, 2018—T. Alp Ikizler, MD, an internationally known expert on the nutritional and metabolic aspects of kidney disease, will succeed Raymond Harris, MD, as director of the Department of Medicine’s Division of Nephrology and Hypertension in the Vanderbilt University School of Medicine effective July 1.
Oct. 13, 2017—Vanderbilt investigators have developed a new mouse model of kidney fibrosis, which provides a platform for identifying new targets and treatment strategies.
Sep. 28, 2017—Vanderbilt’s Division of Nephrology and Hypertension has received a five-year, $5 million federal grant to provide core research services in the fight against kidney disease.
Sep. 11, 2017—Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.
Nov. 12, 2015—A signaling protein that is essential for recovery from acute kidney injury works by increasing the population of tissue-repairing immune cells.
Nov. 12, 2015—Ray Harris, M.D., has been elected president of the American Society of Nephrology during the society’s annual meeting, ASN Kidney Week 2015, in San Diego.
Oct. 22, 2015—A team of Vanderbilt University Medical Center scientists are closer to understanding why COX-2 inhibitors — drugs that relieve arthritis pain and inflammation without the gastrointestinal side effects of other painkillers — cause heart problems in some patients. Now
Jun. 11, 2015—Vanderbilt University researchers have come closer to solving a mystery that has puzzled scientists for more than a century: after the loss of one kidney, what causes the growth of the remaining kidney to take up the slack?